MobiHealth News June 21, 2022
Emily Olsen

Of the 224 companies analyzed, 98 received a clinical robustness score of zero.

Many venture-backed digital health startups aren’t clinically robust, as measured by the number of regulatory filings and clinical trials, according to a study published in JMIR.

The analysis examined digital health companies using the Rock Health Digital Health Venture Funding Database, FDA data on 510(k), De Novo and premarket approval filings, and the number and type of clinical trials listed on ClinicalTrials.gov. Researchers then assigned a “clinical robustness” score for each company, the sum of the number of regulatory filings and clinical trials weighted equally.

Of the 224 startups included in the study, 98 had a clinical robustness score of 0, while 45 received a...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Clinical Trials, Digital Health, FDA, Govt Agencies, Technology, Trends
How Remote Patient Monitoring and AI Personalize Care
Digital Platforms Streamline Medication Access and Delivery
Too much data? Wearables for senior care have value but providers must know how to parse their output, experts say
Novel tech to answer nature’s call: Smartphone app provides real-time bladder data for seniors who need assistance
25 best healthcare software companies, per Healthcare Technology Report

Share This Article